Published in Ann Oncol on July 24, 2009
Getting TRAIL back on track for cancer therapy. Cell Death Differ (2014) 1.86
On the TRAIL to successful cancer therapy? Predicting and counteracting resistance against TRAIL-based therapeutics. Oncogene (2012) 1.75
Phase I Imaging and Pharmacodynamic Trial of CS-1008 in Patients With Metastatic Colorectal Cancer. J Clin Oncol (2015) 1.49
TRAIL on trial: preclinical advances in cancer therapy. Trends Mol Med (2013) 1.49
Advances in targeting cell surface signalling molecules for immune modulation. Nat Rev Drug Discov (2013) 1.46
Death receptors as targets in cancer. Br J Pharmacol (2013) 1.24
Aldehyde dehydrogenase (ALDH) activity does not select for cells with enhanced aggressive properties in malignant melanoma. PLoS One (2010) 1.15
Apoptotic and antitumor activity of death receptor antibodies require inhibitory Fcγ receptor engagement. Proc Natl Acad Sci U S A (2012) 1.11
Inhibition of NF-kappaB signaling by quinacrine is cytotoxic to human colon carcinoma cell lines and is synergistic in combination with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) or oxaliplatin. J Biol Chem (2010) 1.10
Phase I trial and pharmacokinetic study of lexatumumab in pediatric patients with solid tumors. J Clin Oncol (2012) 0.99
Regulating TRAIL receptor-induced cell death at the membrane : a deadly discussion. Recent Pat Anticancer Drug Discov (2011) 0.97
Applications of minimal physiologically-based pharmacokinetic models. J Pharmacokinet Pharmacodyn (2012) 0.97
Blocks to thyroid cancer cell apoptosis can be overcome by inhibition of the MAPK and PI3K/AKT pathways. Cell Death Dis (2014) 0.96
Killing of resistant cancer cells with low Bak by a combination of an antimesothelin immunotoxin and a TRAIL Receptor 2 agonist antibody. Clin Cancer Res (2011) 0.92
Harnessing the cell death pathway for targeted cancer treatment. Am J Cancer Res (2010) 0.91
Sorafenib sensitizes solid tumors to Apo2L/TRAIL and Apo2L/TRAIL receptor agonist antibodies by the Jak2-Stat3-Mcl1 axis. PLoS One (2013) 0.91
TRAIL receptor signaling and therapeutic option in bone tumors: the trap of the bone microenvironment. Am J Cancer Res (2011) 0.88
TRAIL (TNF-related apoptosis-inducing ligand) regulates adipocyte metabolism by caspase-mediated cleavage of PPARgamma. Cell Death Dis (2013) 0.88
Safety, pharmacokinetics, and pharmacodynamics of the DR5 antibody LBY135 alone and in combination with capecitabine in patients with advanced solid tumors. Invest New Drugs (2013) 0.87
A set of NF-κB-regulated microRNAs induces acquired TRAIL resistance in lung cancer. Proc Natl Acad Sci U S A (2015) 0.86
Dacarbazine and the agonistic TRAIL receptor-2 antibody lexatumumab induce synergistic anticancer effects in melanoma. PLoS One (2012) 0.86
Targeting TNF-related apoptosis-inducing ligand (TRAIL) receptor by natural products as a potential therapeutic approach for cancer therapy. Exp Biol Med (Maywood) (2015) 0.86
Antibody phage display libraries: contributions to oncology. Int J Mol Sci (2012) 0.85
Targeting the apoptosis pathway in hematologic malignancies. Leuk Lymphoma (2014) 0.85
Methionine Deprivation Induces a Targetable Vulnerability in Triple-Negative Breast Cancer Cells by Enhancing TRAIL Receptor-2 Expression. Clin Cancer Res (2015) 0.84
Salirasib sensitizes hepatocarcinoma cells to TRAIL-induced apoptosis through DR5 and survivin-dependent mechanisms. Cell Death Dis (2013) 0.83
Combination effects of SMAC mimetic birinapant with TNFα, TRAIL, and docetaxel in preclinical models of HNSCC. Laryngoscope (2014) 0.81
Therapeutic applications of TRAIL receptor agonists in cancer and beyond. Pharmacol Ther (2015) 0.80
Approaches to improve tumor accumulation and interactions between monoclonal antibodies and immune cells. MAbs (2012) 0.80
Potential of apoptotic pathway-targeted cancer therapeutic research: Where do we stand? Cell Death Dis (2016) 0.77
Activating Death Receptor DR5 as a Therapeutic Strategy for Rhabdomyosarcoma. ISRN Oncol (2012) 0.77
A New Player in the Development of TRAIL Based Therapies for Hepatocarcinoma Treatment: ATM Kinase. Cancers (Basel) (2012) 0.76
Physapubescin selectively induces apoptosis in VHL-null renal cell carcinoma cells through down-regulation of HIF-2α and inhibits tumor growth. Sci Rep (2016) 0.76
First-in-human study of the antibody DR5 agonist DS-8273a in patients with advanced solid tumors. Invest New Drugs (2017) 0.76
Targeting death receptors: is this trail still hot? Transl Pediatr (2013) 0.75
Targeted immunotherapy for pediatric solid tumors. Oncoimmunology (2015) 0.75
TRAIL-death receptor endocytosis and apoptosis are selectively regulated by dynamin-1 activation. Proc Natl Acad Sci U S A (2017) 0.75
Dual Agonist Surrobody Simultaneously Activates Death Receptors DR4 and DR5 to Induce Cancer Cell Death. Mol Cancer Ther (2015) 0.75
Targeted approach to metastatic colorectal cancer: what comes beyond epidermal growth factor receptor antibodies and bevacizumab? Ther Adv Med Oncol (2013) 0.75
Enhancing the bystander killing effect of an oncolytic HSV by arming it with a secretable apoptosis activator. Gene Ther (2015) 0.75
Antidrug Antibody Formation in Oncology: Clinical Relevance and Challenges. Oncologist (2016) 0.75
Journey of TRAIL from Bench to Bedside and its Potential Role in Immuno-Oncology. Oncol Rev (2017) 0.75
New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst (2000) 133.74
Physiological parameters in laboratory animals and humans. Pharm Res (1993) 8.14
Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science (1997) 6.82
Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem (1996) 6.22
Apo2L/TRAIL and its death and decoy receptors. Cell Death Differ (2003) 3.66
Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity. Nat Med (2001) 2.87
Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol (2004) 2.04
Phase 1 and pharmacokinetic study of lexatumumab in patients with advanced cancers. Clin Cancer Res (2007) 1.87
Increased death receptor 5 expression by chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor-related apoptosis-inducing ligand in vitro and in vivo. Cancer Res (2000) 1.81
Expression of TRAIL and TRAIL death receptors in stage III non-small cell lung cancer tumors. Clin Cancer Res (2003) 1.29
Expression of TRAIL and TRAIL receptors in normal and malignant tissues. Cell Res (2005) 1.25
Death to the bad guys: targeting cancer via Apo2L/TRAIL. Apoptosis (2005) 1.19
Evaluating the expression and prognostic value of TRAIL-R1 and TRAIL-R2 in breast cancer. Clin Cancer Res (2005) 1.13
Lexatumumab (TRAIL-receptor 2 mAb) induces expression of DR5 and promotes apoptosis in primary and metastatic renal cell carcinoma in a mouse orthotopic model. Cancer Lett (2006) 1.05
Human agonistic TRAIL receptor antibodies Mapatumumab and Lexatumumab induce apoptosis in malignant mesothelioma and act synergistically with cisplatin. Mol Cancer (2007) 1.02
Monoclonal antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 2 (TRAIL-R2) induces apoptosis in primary renal cell carcinoma cells in vitro and inhibits tumor growth in vivo. Int J Oncol (2006) 0.97
Novel in vivo imaging shows up-regulation of death receptors by paclitaxel and correlates with enhanced antitumor effects of receptor agonist antibodies. Mol Cancer Ther (2006) 0.95
Expression of tumour necrosis factor-related apoptosis-inducing ligand death receptors in sporadic and hereditary colorectal tumours: potential targets for apoptosis induction. Eur J Cancer (2005) 0.95
Low concentrations of doxorubicin sensitizes human solid cancer cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-receptor (R) 2-mediated apoptosis by inducing TRAIL-R2 expression. Cancer Sci (2007) 0.91
Drug evaluation: lexatumumab, an intravenous human agonistic mAb targeting TRAIL receptor 2. Curr Opin Mol Ther (2006) 0.85
Human agonistic antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 2 induces cytotoxicity and apoptosis in prostate cancer and bladder cancer cells. Urology (2007) 0.82
Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer. J Natl Cancer Inst (1999) 4.04
Human DNA-activated protein kinase phosphorylates serines 15 and 37 in the amino-terminal transactivation domain of human p53. Mol Cell Biol (1992) 3.68
Pancreatic tumors show high levels of hypoxia. Int J Radiat Oncol Biol Phys (2000) 3.22
Negative growth regulation in a glioblastoma tumor cell line that conditionally expresses human wild-type p53. Proc Natl Acad Sci U S A (1990) 3.20
The receptor-binding sequence of urokinase. A biological function for the growth-factor module of proteases. J Biol Chem (1987) 2.73
The urban homeless: estimating composition and size. Science (1987) 2.43
Mechanisms of action of and resistance to antitubulin agents: microtubule dynamics, drug transport, and cell death. J Clin Oncol (1999) 2.43
Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules. Br J Cancer (2003) 2.38
Perioperative total parenteral nutrition in malnourished, gastrointestinal cancer patients: a randomized, clinical trial. JPEN J Parenter Enteral Nutr (2000) 2.36
Detection of cell-affecting agents with a silicon biosensor. Science (1989) 2.31
Fifteen-year results of a randomized phase III trial of fenretinide to prevent second breast cancer. Ann Oncol (2006) 2.10
A therapy planning architecture that combines decision theory and artificial intelligence techniques. Comput Biomed Res (1987) 2.09
A mouse tumor-specific transplantation antigen is a heat shock-related protein. Proc Natl Acad Sci U S A (1986) 2.06
Subtotal versus total gastrectomy for gastric cancer: five-year survival rates in a multicenter randomized Italian trial. Italian Gastrointestinal Tumor Study Group. Ann Surg (1999) 2.00
Growth suppression induced by wild-type p53 protein is accompanied by selective down-regulation of proliferating-cell nuclear antigen expression. Proc Natl Acad Sci U S A (1991) 1.99
Growth arrest induced by wild-type p53 protein blocks cells prior to or near the restriction point in late G1 phase. Proc Natl Acad Sci U S A (1992) 1.90
Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma. Blood (1997) 1.85
Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy. Proc Natl Acad Sci U S A (2001) 1.85
Vascular integrin alpha(v)beta3: a new prognostic indicator in breast cancer. Clin Cancer Res (1998) 1.80
Functional inactivation but not structural mutation of p53 causes liver cancer. Nat Genet (1995) 1.80
Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein. Cancer Chemother Pharmacol (1997) 1.73
Tumor necrosis factor (TNF) receptor superfamily member TACI is a high affinity receptor for TNF family members APRIL and BLyS. J Biol Chem (2000) 1.72
Mutation of the serine 15 phosphorylation site of human p53 reduces the ability of p53 to inhibit cell cycle progression. Oncogene (1993) 1.63
Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate. Ann Oncol (2008) 1.63
Dose-response of birth weight to various measures of maternal smoking during pregnancy. J Clin Epidemiol (1988) 1.62
Evaluation of LRRK2 G2019S penetrance: relevance for genetic counseling in Parkinson disease. Neurology (2007) 1.61
Time distribution of the recurrence risk for breast cancer patients undergoing mastectomy: further support about the concept of tumor dormancy. Breast Cancer Res Treat (1996) 1.61
Decreased mutation rate for cellular resistance to doxorubicin and suppression of mdr1 gene activation by the cyclosporin PSC 833. J Natl Cancer Inst (1995) 1.60
Incidence and predictors of bleeding events after fibrinolytic therapy with fibrin-specific agents: a comparison of TNK-tPA and rt-PA. Eur Heart J (2001) 1.58
A novel cytokine receptor-ligand pair. Identification, molecular characterization, and in vivo immunomodulatory activity. J Biol Chem (2000) 1.54
Status of surgical margins and prognosis in adult soft tissue sarcomas of the extremities: a series of patients treated at a single institution. J Clin Oncol (2005) 1.51
Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a phase II trial. J Clin Oncol (2000) 1.50
Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance. J Clin Oncol (1992) 1.49
Wild type human p53 is antiproliferative in SV40-transformed hamster cells. Oncogene (1990) 1.47
The ezrin-like family of tyrosine kinase substrates: receptor-specific pattern of tyrosine phosphorylation and relationship to malignant transformation. Oncogene (1993) 1.44
Multidrug (pleiotropic) resistance in doxorubicin-selected variants of the human sarcoma cell line MES-SA. Cancer Res (1985) 1.43
Low or absent SPARC expression in acute myeloid leukemia with MLL rearrangements is associated with sensitivity to growth inhibition by exogenous SPARC protein. Leukemia (2006) 1.42
Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors. Ann Oncol (2012) 1.40
Prenatal exposure to tobacco: II. Effects on cognitive functioning at age three. Int J Epidemiol (1990) 1.40
Multifactorial mechanisms associated with broad cross-resistance of ovarian carcinoma cells selected by cyanomorpholino doxorubicin. Cancer Res (1991) 1.39
Gastrin releasing peptide is a selective mitogen for small cell lung carcinoma in vitro. J Clin Invest (1985) 1.33
Interaction of anti-HIV protease inhibitors with the multidrug transporter P-glycoprotein (P-gp) in human cultured cells. J Acquir Immune Defic Syndr Hum Retrovirol (1998) 1.32
Total versus subtotal gastrectomy: surgical morbidity and mortality rates in a multicenter Italian randomized trial. The Italian Gastrointestinal Tumor Study Group. Ann Surg (1997) 1.32
Multidrug resistance (mdr1) gene expression in adult acute leukemias: correlations with treatment outcome and in vitro drug sensitivity. Blood (1991) 1.29
Modulation of multidrug resistance: at the threshold. J Clin Oncol (1993) 1.28
Breast cancer recurrence dynamics following adjuvant CMF is consistent with tumor dormancy and mastectomy-driven acceleration of the metastatic process. Ann Oncol (2005) 1.27
Phase I trial of doxorubicin with cyclosporine as a modulator of multidrug resistance. J Clin Oncol (1994) 1.25
Resistance mechanisms in human sarcoma mutants derived by single-step exposure to paclitaxel (Taxol). Cancer Res (1996) 1.23
Brief report: trimethoprim-induced hyperkalemia in a patient with AIDS. N Engl J Med (1993) 1.20
A Phase 1b/2 trial of mapatumumab in patients with relapsed/refractory non-Hodgkin's lymphoma. Br J Cancer (2010) 1.19
Pharmacokinetics and protein binding of cis-dichlorodiammine platinum (II) administered as a one hour or as a twenty hour infusion. Cancer Chemother Pharmacol (1980) 1.16
Murine 86- and 84-kDa heat shock proteins, cDNA sequences, chromosome assignments, and evolutionary origins. J Biol Chem (1989) 1.16
Prevalence of multidrug resistance related to activation of the mdr1 gene in human sarcoma mutants derived by single-step doxorubicin selection. Cancer Res (1994) 1.16
The carboxy-terminal serine 392 phosphorylation site of human p53 is not required for wild-type activities. Oncogene (1994) 1.15
Multidrug resistance in lymphomas. J Clin Oncol (1994) 1.13
STRL22 is a receptor for the CC chemokine MIP-3alpha. Biochem Biophys Res Commun (1997) 1.13
Metabolism of round spermatids from rats: lactate as the preferred substrate. Biol Reprod (1982) 1.09
Novel mechanism of resistance to paclitaxel (Taxol) in human K562 leukemia cells by combined selection with PSC 833. Oncol Res (1995) 1.09
Inhibition by brefeldin A of presentation of exogenous protein antigens to MHC class II-restricted T cells. Nature (1990) 1.08
Sorafenib with interleukin-2 vs sorafenib alone in metastatic renal cell carcinoma: the ROSORC trial. Br J Cancer (2011) 1.08
Clinical relevance of vascular endothelial growth factor and thymidine phosphorylase in patients with node-positive breast cancer treated with either adjuvant chemotherapy or hormone therapy. Cancer J Sci Am (1999) 1.08
Correlation of CT findings with clinical evaluations in 261 patients with symptomatic bronchiectasis. AJR Am J Roentgenol (1999) 1.07
Continuous infusion or bolus injection in cancer chemotherapy. Ann Intern Med (1983) 1.06
Clinical studies with modulators of multidrug resistance. Hematol Oncol Clin North Am (1995) 1.06
Occupational allergy to laboratory animals: an epidemiologic study. J Occup Med (1986) 1.05
Clinical trials of modulation of multidrug resistance. Pharmacokinetic and pharmacodynamic considerations. Cancer (1993) 1.05
Tumour markers CEA, NSE, SCC, TPA and CYFRA 21.1 in resectable non-small cell lung cancer. Anticancer Res (2000) 1.04
Reoperation for locally recurrent breast cancer in patients previously treated with conservative surgery. Br J Surg (1999) 1.04
Treatment of refractory and relapsed acute myelogenous leukemia with combination chemotherapy plus the multidrug resistance modulator PSC 833 (Valspodar). Blood (1999) 1.03
A multicenter phase II study of pazopanib in patients with advanced gastrointestinal stromal tumors (GIST) following failure of at least imatinib and sunitinib. Ann Oncol (2014) 1.03
Development and characterization of a human sarcoma cell line, MES-SA, sensitive to multiple drugs. Cancer Res (1983) 1.02
Frontline extended surgery is associated with improved survival in retroperitoneal low- to intermediate-grade soft tissue sarcomas. Ann Oncol (2011) 1.02
Improved therapeutic index of bleomycin when administered by continuous infusion in mice. Cancer Treat Rep (1978) 1.02
Tumor stage, human papillomavirus and smoking status affect the survival of patients with oropharyngeal cancer: an Italian validation study. Ann Oncol (2011) 1.02
The general concepts of an equivalence trial, applied to ASSENT-2, a large-scale mortality study comparing two fibrinolytic agents in acute myocardial infarction. Eur Heart J (2001) 1.01
Treatment of angioimmunoblastic T-cell lymphoma with cyclosporine. Ann Oncol (1997) 1.01
Phase I trial of etoposide with cyclosporine as a modulator of multidrug resistance. J Clin Oncol (1992) 1.01
Cloning, sequencing, and expression of Arthrobacter protophormiae endo-beta-N-acetylglucosaminidase in Escherichia coli. Arch Biochem Biophys (1997) 1.01
Pulmonary toxicity of antitumor agents. Cancer Treat Rev (1983) 1.00
TNK-tissue plasminogen activator in acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) 10A dose-ranging trial. Circulation (1997) 0.99
Erlotinib 'dosing-to-rash': a phase II intrapatient dose escalation and pharmacologic study of erlotinib in previously treated advanced non-small cell lung cancer. Br J Cancer (2011) 0.99
Verapamil-mediated sensitization of doxorubicin-selected pleiotropic resistance in human sarcoma cells: selectivity for drugs which produce DNA scission. Cancer Res (1986) 0.99
Phase I/II trial of biweekly paclitaxel and cisplatin in the treatment of metastatic breast cancer. J Clin Oncol (1996) 0.98
Conformational studies of the interdomain linker peptides in the dihydrolipoyl acetyltransferase component of the pyruvate dehydrogenase multienzyme complex of Escherichia coli. J Biol Chem (1992) 0.98
Multidrug-resistant human sarcoma cells with a mutant P-glycoprotein, altered phenotype, and resistance to cyclosporins. J Biol Chem (1997) 0.98
Pathological features as predictors of recurrence after radical resection of gastric cancer. Br J Surg (2006) 0.97
Characterization of a chemically homogeneous tumor antigen from a methylcholanthrene-induced sarcoma, Meth A. Mol Immunol (1986) 0.97
Cloning and nucleotide sequence of the murine hsp84 cDNA and chromosome assignment of related sequences. Gene (1987) 0.97
Comparative analysis of breast cancer recurrence risk for patients receiving or not receiving adjuvant cyclophosphamide, methotrexate, fluorouracil (CMF). Data supporting the occurrence of 'cures'. Breast Cancer Res Treat (1999) 0.97
Phase I study of an antisense oligonucleotide to protein kinase C-alpha (ISIS 3521/CGP 64128A) in patients with cancer. Clin Cancer Res (1999) 0.96
Keratinocyte growth factor-2 (FGF-10) promotes healing of experimental small intestinal ulceration in rats. Am J Physiol Gastrointest Liver Physiol (2000) 0.96
Is steroid receptor profile in contralateral breast cancer a marker of independence of the corresponding primary tumour? Eur J Cancer (1998) 0.95
Dissociation of antitumor potency from anthracycline cardiotoxicity in a doxorubicin analog. Science (1985) 0.95
Phase I and pharmacokinetic study of BMS-184476, a taxane with greater potency and solubility than paclitaxel. J Clin Oncol (2001) 0.95